These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19714814)

  • 1. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57.
    Cicchillitti L; Di Michele M; Urbani A; Ferlini C; Donat MB; Scambia G; Rotilio D
    J Proteome Res; 2009 Apr; 8(4):1902-12. PubMed ID: 19714814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines.
    Di Michele M; Della Corte A; Cicchillitti L; Del Boccio P; Urbani A; Ferlini C; Scambia G; Donati MB; Rotilio D
    Biochim Biophys Acta; 2009 Feb; 1794(2):225-36. PubMed ID: 18973835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterisation of a multimeric protein complex associated with ERp57 within the nucleus in paclitaxel-sensitive and -resistant epithelial ovarian cancer cells: the involvement of specific conformational states of beta-actin.
    Cicchillitti L; Della Corte A; Di Michele M; Donati MB; Rotilio D; Scambia G
    Int J Oncol; 2010 Aug; 37(2):445-54. PubMed ID: 20596672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers.
    Di Michele M; Marcone S; Cicchillitti L; Della Corte A; Ferlini C; Scambia G; Donati MB; Rotilio D
    J Proteomics; 2010 Mar; 73(5):879-98. PubMed ID: 19951750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel.
    Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y
    Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines.
    Chen M; Huang H; He H; Ying W; Liu X; Dai Z; Yin J; Mao N; Qian X; Pan L
    Cancer Sci; 2015 Aug; 106(8):1075-83. PubMed ID: 26033570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of REST and TUBB3 in ovarian cancer and its relationship to paclitaxel resistance.
    Gao S; Zhao X; Lin B; Hu Z; Yan L; Gao J
    Tumour Biol; 2012 Oct; 33(5):1759-65. PubMed ID: 22684772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.
    Feng J; Peng Z; Gao L; Yang X; Sun Z; Hou X; Li E; Zhu L; Yang H
    Biomed Pharmacother; 2021 Jun; 138():111407. PubMed ID: 33765585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells.
    Lee DH; Chung K; Song JA; Kim TH; Kang H; Huh JH; Jung SG; Ko JJ; An HJ
    J Proteome Res; 2010 Nov; 9(11):5668-76. PubMed ID: 20858016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative proteomic analysis of paclitaxel sensitive A549 lung adenocarcinoma cell line and its resistant counterpart A549-Taxol.
    Sun QL; Sha HF; Yang XH; Bao GL; Lu J; Xie YY
    J Cancer Res Clin Oncol; 2011 Mar; 137(3):521-32. PubMed ID: 20499251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of patupilone resistance.
    Mozzetti S; Iantomasi R; De Maria I; Prislei S; Mariani M; Camperchioli A; Bartollino S; Gallo D; Scambia G; Ferlini C
    Cancer Res; 2008 Dec; 68(24):10197-204. PubMed ID: 19074887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic analysis of human ovarian cancer paclitaxel-resistant cell lines.
    Cao L; Li X; Zhang Y; Peng F; Yi H; Xu Y; Li X; Wang Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Apr; 35(4):286-94. PubMed ID: 20448348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
    Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
    Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA; Chen T; Taylor CC
    Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
    Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
    Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.
    Le Moguen K; Lincet H; Deslandes E; Hubert-Roux M; Lange C; Poulain L; Gauduchon P; Baudin B
    Proteomics; 2006 Oct; 6(19):5183-92. PubMed ID: 16941573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
    Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
    J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
    Duran GE; Wang YC; Moisan F; Francisco EB; Sikic BI
    Br J Cancer; 2017 May; 116(10):1318-1328. PubMed ID: 28399108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.